VersKiK: Study protocol of an observational registry-based study on the current state of follow-up care and adherence to follow-up guidelines after cancer in childhood or adolescence
Ekaterina Aleshchenko(Otto-von-Guericke-Universität Magdeburg), P. Trocchi(Otto-von-Guericke-Universität Magdeburg), Ursula Marschall(BARMER GEK), Isabelle Meier(Techniker Krankenkasse (Germany)), T. Kloppe(Oldenburger Institut für Informatik), Gabriele Calaminus(University Hospital Bonn), Jutta Kuepper‐Nybelen(University of Cologne), P Droege, Enno Swart(Otto-von-Guericke-Universität Magdeburg), Hiltrud Merzenich(Johannes Gutenberg University Mainz), Dirk Horenkamp‐Sonntag(Techniker Krankenkasse (Germany)), Peter Ihle(University Hospital Cologne), Claudia Spix(Johannes Gutenberg University Mainz), Thorsten Langer, Katja Baust(University Hospital Bonn), Christian Apfelbacher(Heidelberg University), J. Glogner(University Hospital Bonn), Melanie Klein(DAK-Gesundheit (Germany)), C. Luepkes(Oldenburger Institut für Informatik), Peter Kaatsch(Johannes Gutenberg University Mainz)
Cited by 5
Related Papers
International Classification of Childhood Cancer, third edition
|Cancer|2005|1.5k
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419